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OBJECTIVE — Individuals with type 2 diabetes have a myriad of metabolic aberrations
including increased inﬂammation, increasing their cardiovascular risk. Toll-like receptors
(TLRs) and their ligands play a key role in insulin resistance and atherosclerosis. However, there
isapaucityofdataexaminingtheexpressionandactivityofTLRsintype2diabetes.Thus,inthe
present study, we examined TLR2 and TLR4 mRNA and protein expression, their ligands, and
signaling in monocytes of recently diagnosed type 2 diabetic patients.
RESEARCH DESIGN AND METHODS — TLR mRNA, protein expression, TLR li-
gands, and TLR signaling were measured in freshly isolated monocytes from healthy human
controlsubjects(n23)andtype2diabeticsubjects(n23)usingreal-timeRT-PCR,Western
blot, and ﬂow cytometric assays.
RESULTS — Type 2 diabetic subjects had signiﬁcantly increased TLR2, TLR4 mRNA, and
protein in monocytes compared with control subjects (P  0.05). Increased TLR2 and TLR4
expression correlated with BMI, homeostasis model assessment–insulin resistance (HOMA-IR),
glucose, A1C, N
ε -(carboxymethyl) lysine (CML), and free fatty acid (FFA). Ligands of TLR2 and
TLR4,namely,HSP60,HSP70,HMGB1,endotoxin,andhyaluronanlevels,wereelevatedintype
2 diabetic subjects and positively correlated with TLR2 and TLR4. Type 2 diabetic subjects
showed increased MyD88, phosphorylated IRAK-1, Trif, TICAM-1, IRF-3, and NF-B p65
expression in monocytes compared with control subjects. Furthermore, TLR-MyD88-NF-B
signaling resulted in elevated levels of cytokines (P  0.05), but increased interleukin (IL)-1,
interferon (IFN)-, and endotoxin were not signiﬁcant when adjusted for BMI.
CONCLUSIONS — In this comprehensive study, we make the novel observation that TLR2
and TLR4 expression and their ligands, signaling, and functional activation are increased in
recently diagnosed type 2 diabetes and contribute to the proinﬂammatory state.
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T
ype2diabetesconstitutesagroupof
metabolic aberrations including hy-
perglycemia, inﬂammation, and in-
sulin resistance that increase the risk of
cardiovascular disease (1). The mecha-
nisms by which these metabolic abnor-
malities cause cardiovascular disease are
not clear. Considerable evidence indi-
cates that the harmful effects of elevated
glucosearemediatedbyreceptorsleading
to increased inﬂammation and oxidative
stress(2,3).Recentstudiesdemonstrating
associations between elevated levels of
circulating C-reactive protein, proinﬂam-
matory cytokines, and homeostasis
model assessment–insulin resistance
(HOMA-IR) suggest that inﬂammation is
an important etiological factor in the de-
velopment of both insulin resistance and
type 2 diabetes (4). Moreover, inﬂamma-
tory markers link the pathology of insulin
resistance and type 2 diabetes. Activation
of the innate immune system via toll-like
receptors (TLRs) is implicated in the
pathogenesis of insulin resistance, dia-
betes, and atherosclerosis (5–7). Com-
plimentary genetic studies link TLR2
and TLR4 polymorphisms to type 2 di-
abetes, suggesting a casual relationship
between TLR function and diabetes and
its complications (8).
TLRs are evolutionarily preserved
pattern-recognition receptors (9), ex-
pressed on several cell types including
monocytes, predominant cells of the in-
nate immune system that are pivotal in
diabetes and atherogenesis (10). TLRs
play an important role in the activation
and regulation of the innate immune sys-
tem and inﬂammation (9). Each TLR
family member recognizes a speciﬁc
pathogen component, upon activation,
triggers a signaling cascade leading to cy-
tokine production and adaptive immune
response (9). Among the TLRs, TLR2 and
TLR4 play a critical role in the pathogen-
esis of insulin resistance, diabetes, and
atherosclerosisinbothclinicalandexper-
imental conditions (5–7,11). Ligands for
TLR2 and TLR4 include high-mobility
group B1 protein (HMGB1), heat shock
protein (HSP) 60, HSP70, endotoxin,
hyaluronan, advanced glycation end
products, and extracellular matrix com-
ponents (12). TLR2 and TLR4 bind to
components of the gram-positive and
-negative bacteria, respectively (12).
TLR2 has broad ligand recognition spec-
iﬁcity because of its ability to form het-
erodimers with TLR1, TLR6, and
sometimes with CD14 and CD36 (13).
TLR4 does not recognize endotoxin with-
out the cofactor MD-2 (14). Collectively,
these ligands and cofactors markedly in-
crease TLR functionality and have not
been studied in type 2 diabetes.
TLR2andTLR4expressionhavebeen
showntobeincreasedinconventionalin-
sulin resistance target tissues like skeletal
muscle and adipose tissue of type 2 dia-
betic subjects (15,16). These important
studies implicating TLRs in type 2 diabe-
tes were derived using small sample size,
and the association with respective TLR2/
TLR4 ligands, cofactors, downstream sig-
naling, and functional activation remains
to be properly addressed. Moreover, sys-
temic inﬂammation plays a signiﬁcant
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type 2 diabetes, and the role of TLR2
and TLR4 in this setting is not clear.
Experimental evidence in mice demon-
strates that TLR2 and TLR4 activation
and downstream cytokine production
lead to the development of diabetes
(17,18). More recently, TLR4 has been
indicated as a molecular link between
free fatty acids (FFAs), inﬂammation,
and the innate immune system (5).
Also,Songetal.(19)reportedincreased
TLR4 mRNA expression in differentiat-
ing adipose tissue of db/db mice.
While these important observations
from animal and human tissue data sug-
gest a role for TLR2 and TLR4 in type 2
diabetes, it remains unknown whether
alterations in TLR2 and TLR4 pathway
activation contribute to systemic in-
ﬂammation in diabetic human subjects.
Therefore,thepurposeofthisstudywas
to undertake a comprehensive analysis
of TLR2 and TLR4 activation, ligands,
cofactors, and downstream signaling in
monocytes isolated from recently diag-
nosed patients with type 2 diabetes and
matched control subjects.
RESEARCH DESIGN AND
METHODS— Type 2 diabetic pa-
tients (n  23) (with mean duration of
diabetes  29 months; age 35 years)
were recruited from the Diabetes and Pe-
diatric Clinics at University of California
Davis Medical Center. None of the pa-
tients were on thiazolidinediones, ACE
inhibitors, angiotensin receptor blockers,
insulin, or statins, since they interfere
with TLR expression and activation; six
type 2 diabetic subjects were on met-
formin. Healthy control subjects (n 
23), age 35 years, with normal com-
plete blood count; no family history of
diabetesorotherchronicdiseases;normal
kidney, liver, and thyroid function; and
fasting plasma glucose 100 mg/dl were
included in the study. Healthy control
subjects and type 2 diabetic patients were
matched for age (within 5–10 years), sex,
and race. Subjects with mean A1C over
the last year 10%; inﬂammatory disor-
ders; microvascular and macrovascular
complications; abnormal liver, renal, or
thyroid function; steroid therapy, anti-
inﬂammatory, antihypertensive, or hypo-
lipidemic drugs; antioxidant supplements
inthepast3months;pregnancy;smoking;
abnormal complete blood count; alcohol
consumption1oz/day;consumptionof
omega-3 polyunsaturated fatty acid cap-
sules (1 g/day); and chronic high-
intensity exercisers were excluded.
Informed consent was obtained from all
the subjects, and the study was approved
by the University of California Davis In-
stitutional Review Board. After history
and physical examination, fasting blood
(30 ml) was obtained. All the type 2 dia-
betic patients had family history of diabe-
tes. Of the subjects, 60% were Caucasian
and the remaining 40% were Hispanic
and African American.
Complete blood count, lipid and li-
poprotein proﬁle, glucose, A1C, C-
peptide, and C-reactive protein in all the
enrolled subjects were assayed by stan-
dardlaboratorytechniques(11).FFAlev-
els were assayed using reagents from
Wako Chemicals (Richmond). Fasting
plasma insulin concentrations were mea-
suredusinganenzyme-linkedimmunosor-
bent assay (ELISA) (Linco Research).
Insulin sensitivity was estimated by
HOMA-IR (20).
Human monocytes
Human monocytes were isolated by gra-
dient density centrifugation of peripheral
blood using Histopaque (Sigma) and
magnetic separation (Miltenyi Biotech) as
reported previously (3,11). More than
88% of cells were identiﬁed as monocytes
byCD14staining,andviabilitywasfound
to be 92%. Monocytes were examined
before and after activation with synthetic
lipoprotein Pam3Cys-Ser-(Lys) 4 (TLR2
ligand; Pam3CSK4, 170 ng/ml; Invitro-
gen) and lipopolysaccharide (LPS) (TLR4
ligand; 160 ng/ml; E. coli 026:B6; Sigma)
overnight (12 h), with suitable control
subjects (3,11). After treatment, cells
were incubated with TLR2, TLR4, or iso-
type-matched IgG (eBioscience) depend-
ing on the cell treatment; 10,000 events
wereanalyzedwiththeBecton-Dickinson
Fluorescence-Activated Cell Sorter Bio-
analyzer as described previously (11) af-
ter gating for CD14. Intra-assay and
interassay coefﬁcient of variation (CV) for
TLR2 and TLR4 expression was 8 and
12%, respectively (3,11).
Serum and cell supernatants were
used for measuring interleukin (IL)-1,
IL-6, IL-8, interferon (IFN)-, monocyte
chemoattractant protein (MCP)-1, and
tumor necrosis factor (TNF)- with a
Multiplexassay(Millipore)asafunctional
readoutofTLRactivation.IFN-(Antige-
nix America), HSP60, HSP70 (Assay De-
signs), HMGB1 (Shino-Test, Japan),
hyaluronan (Echelon), and N
ε -(carboxy-
methyl) lysine (CML) (CycLex, Japan)
were determined using ELISA in the se-
rumofallstudysubjects.Nuclearextracts
were used to verify activation of NF-B
(Active Motif) in study subjects, indicat-
ing increased inﬂammation, as described
previously (3,11). Intra- and interassay
CV for all the assays were determined to
be between 7 and 12% (21). All the re-
agents used in the study were tested for
endotoxin (100 ELISA unit [EU]/ml)
using a Limulus ameobocyte lysate assay
(Lonza), allowing precise TLR expression
measurements devoid of endotoxin
(3,11).
Real-time RT-PCR
RNA was isolated from monocytes using
TRI reagent (Invitrogen). cDNA was syn-
thesized using 1 g total RNA, and 50 ng
was ampliﬁed using primer probe sets for
TLR1,TLR2,TLR4,TLR6,MD-2,and18s
(SA Bioscience) following manufacturer’s







Monocyte cell lysates were subjected to
electrophoresis and transfer, as reported
earlier (3,11). Blots were probed with hu-
man myeloid differentiation factor-88
(MyD88), IL receptor–associated protein
kinase-1 (IRAK-1), toll–IL-1 receptor do-
main (TIR)-containing adaptor molecule
(TICAM-2),IFNregulatoryfactor-3(IRF-
3), NF-B (NF-Bp65; Santa Cruz Bio-
technology, Santa Cruz, CA), TIR-
containing adapter-inducing IFN- (Trif;
Abcam), and antibodies with respective
secondary IgG antibodies and developed.
In all assays, -actin and total nonphos-
phorylated proteins were used as internal
control. Besides, cell lysates (100 g)
were immunoprecipitated with TLR2 or
TLR4 antibody overnight at 4°C as re-
ported previously (3) and blotted with
TLR6, HMGB1, HSP60 (Santa Cruz),
and hyaluronan (Ray Biotech) antibod-
ies as depicted in Fig. 2F and G. Densi-
tometric ratios were determined as
reported earlier from four independent
assays (3,11).
Statistical analysis
Statistical analyses were performed using
SAS software (SAS Institute, Cary, NC).
Data are expressed as means  SD for all
data.Parametricdatawereanalyzedusing
paired,two-tailedttestsandnonparamet-
ric data using Wilcoxon’s signed-rank
tests. Level of signiﬁcance was set at P 
0.05. Spearman’s rank correlation was
TLR2 and TLR4 expression and activation in type 2 diabetes
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RESULTS
Baseline characteristics of the study
subjects
Subject characteristics are detailed in
Table 1. There were no signiﬁcant dif-
ferencesinageandlipidproﬁlebetween
control and type 2 diabetes groups.
Levels of glucose, A1C, FFAs, and
HOMA-IR were signiﬁcantly higher in
type 2 diabetic subjects than in control
subjects. C-peptide and advanced gly-
cationendproductandCMLlevelswere
signiﬁcantlyincreasedintype2diabetic
subjects compared with control sub-
jects. C-reactive protein, a prototypic
atherosclerotic marker, is increased in
type 2 diabetic subjects compared with
control subjects.
TLR2 and TLR4 mRNA and protein
expression in type 2 diabetes
monocytes
We ﬁrst determined the levels of TLR2
and TLR4 expression by ﬂow cytometric
analysis in control and type 2 diabetic
subjects. Monocyte surface expression of
TLR2andTLR4wassigniﬁcantlyelevated
in type 2 diabetes compared with control
in both the resting and activated state
(Pam3CSK4 or LPS) (Fig. 1A and D, P 
0.005). Next, to determine if the increase
in monocyte TLR2 and TLR4 expression
in type 2 diabetes resulted from increased
mRNA expression, we investigated the
TLR2andTLR4mRNAlevelsbyreal-time
RT-PCR. Figure 1B and E depict the cor-
responding increased TLR2 and TLR4
mRNAexpressionintype2diabetescom-
pared with control subjects. We further
conﬁrmed the increased monocyte TLR2
and TLR4 protein content using Western
blot assay (Fig. 1C and F). We measured
downstream functional readouts (IL-1,
IL-6,IL-8,andTNF-)ofTLR2/4ligation
in resting and activated monocytes (Fig.
1G).Therewasasigniﬁcantupregulationof
proinﬂammatory cytokines in type 2 dia-
betic patients compared with control sub-
jects in both the basal and activated state.
TLR2 and TLR4 ligand and cofactor
expression in type 2 diabetes
Identiﬁcation of TLR2 and TLR4 ligands
and cofactors is a key element in TLR ac-
tivation and is unclear in type 2 diabetic
subjects. Beyond the established micro-
bial ligands of TLR2 and TLR4, several
molecules of endogenous origin have
been suggested to act as TLR2 and TLR4
ligands,notablyHMGB1,HSP60,HSP70,
and hyaluronan fragments. Accordingly,
wemeasuredconcentrationofendotoxin,
HMGB1,hyaluronan,HSP60,andHSP70
in the serum of type 2 diabetic subjects
andcontrolsubjectsusingELISAs.Figure
2 shows the signiﬁcant increased levels of
these ligands in type 2 diabetic subjects.
In addition, coimmunoprecipitation with
TLR2 and TLR4 and blotting for HMGB1,
HSP60, and hyaluronan showed strong
association with both TLR2 and TLR4 in
type 2 diabetes compared with control
subjects (Fig. 2F and G).
It has been previously shown that
TLR2 dimerizes with TLR1 or TLR6 and
results in receptor activation and down-
streamsignalinguponsaturatedfattyacid
challenge.TodeterminewhetherTLR1or
TLR6 is required for the activation of
TLR2, we measured TLR1 and TLR6
mRNA expression in monocytes of type 2
diabetes and control subjects. TLR6
mRNA levels signiﬁcantly increased in
type 2 diabetes (3.8  0.4 vs. 1.3  0.2
mRNA/18s ratio; P  0.05) compared
with control subjects, whereas TLR1
mRNA levels remained unchanged (con-
trol: 1.5  0.4, type 2 diabetes: 1.9  0.5
mRNA/18s ratio), and coimmunoprecipi-
tation showed an increased TLR2/TLR6
association in type 2 diabetes (Fig. 2F).
Further, MD-2 mRNA expression was
alsosigniﬁcantlyincreased(control1.2
0.2vs.2.90.3mRNA/18sratio)intype
2 diabetes monocytes. These data are in
line with our earlier observation that under
hyperglycemic conditions, TLR2 het-
erodimerizes with TLR6 in monocytes (3).
TLR2 and TLR4 activation results in
MyD88-dependent and -independent
signaling in type 2 diabetes
monocytes
We examined the TLR-mediated MyD88-
dependent signaling pathway using
Western blot technique. TLR2 and TLR4
both use MyD88 and activate NF-B,
common downstream signaling compo-
nentsforallTLRsexceptTLR3(3,9).There-
fore, activation of MyD88-dependent and
-independent pathways was used to inter-
pret the activation of TLR2 and TLR4.
Phosphorylation of IRAK-1, MyD88,
TRIF, TECAM-2, IRF-3 protein expres-
sion in cytoplasmic extract, and p65
protein levels in nuclear extracts of
monocytesweresigniﬁcantlyincreasedin
type 2 diabetes compared with control
subjects, with no change in total protein
and -actin levels (Fig. 2H), suggesting
activation of TLR-mediated signaling cas-
cade (both MyD88-dependent and -inde-
pendent) in type 2 diabetes. In addition,
densitometry ratios further corroborate
the data (Fig. 2H).
Increased TLR2 and TLR4
expression results in increased
inﬂammation mediated by NF-B
To further investigate TLR2- and TLR4-
mediated inﬂammation in type 2 diabe-
tes, we measured NF-B activity in the
nuclear extracts of type 2 diabetes and
control subject monocytes. Type 2 diabe-
tes showed increased NF-B p65-
dependent DNA binding activity
Table 1—Clinical and laboratory characteristics
Control Type 2 diabetes P
n 23 23
Sex (M/F) 11/12 9/16
Age (years) 46  12 51  10 NS
BMI (kg/m
2) 25  73 4  9 0.001
Fasting glucose (mmol/l) 4.9  0.5 8.9  3.1 0.0001
Fasting insulin (pmol/l) 79  17 190  120 0.018
HOMA-IR 1.5  0.4 3.7  1.8 0.001
Fasting FFAs (mEq/l) 0.3  0.2 0.9  0.2 0.0001
A1C (%) 5.2  0.2 8  2.1 0.05
C-peptide (ng/ml) 1.2  1 2.5  0.6 0.001
C-reactive peptide (mg/l) 2.9  4 4.7  4 0.002
Total cholesterol (mg/dl) 184  36 190  36 NS
LDL cholesterol (mg/dl) 115  26 120  29 NS
HDL cholesterol (mg/dl) 50  11 39  15 0.3
Triglycerides (mg/dl) 100  62 145  67 0.45
CML (ng/ml) 1.9  1.1 5.4  3.1 0.001
Data are means  SD. P values correspond to the differences between control and type 2 diabetes.
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0.01) (Fig. 2I). Increased NF-B activity
corresponded to increased systemic in-
ﬂammation. We measured IL-1, IL-6,
IL-8, MCP-1, IFN-, and TNF- serum
concentration in type 2 diabetes and con-
trol subjects as a functional readout of
TLRactivation.Therewasasigniﬁcantin-
crease in all the proinﬂammatory media-
tors in type 2 diabetic subjects compared
with control subjects (Fig. 2J and K).
Increased TLR expression correlates
with BMI, glucose, HOMA-IR, and
inﬂammation
Additionally, there was a signiﬁcant cor-
relation between BMI and TLR2 expres-
sion (r  0.5; P  0.05) and TLR4
expression (r  0.43; P  0.01) and sig-
niﬁcant correlation between TLR expres-
sion and glucose (TLR2: r  0.7; TLR4,
r  0.64, P  0.001), FFA levels (TLR2:
r  0.66; TLR4, r  0.66, P  0.05),
HOMA-IR (TLR2: r  0.64; TLR4, r 
0.54, P  0.005), and A1C (TLR2: r 
0.66; TLR4, r  0.62, P  0.001). In ad-
dition, HSP60, HSP70, HMGB1, and en-
dotoxin levels signiﬁcantly correlated
with TLR2 expression (r  0.43, r 
0.64, r  0.48, and r  0.16; P  0.05)
andTLR4expression(r0.43,r0.65,
r  0.41, and r  0.21; P  0.001), re-
spectively. There was a signiﬁcant corre-
lation between TLR2 expression and IL-
Figure 1—TLR protein and mRNA content. A: TLR2 surface protein expression was measured in monocytes after Pam3CSK4 (Pam) challenge in
control(n23)andtype2diabetic(n23)subjectsbyﬂowcytometryasdescribedin RESEARCH DESIGN AND METHODS.Valuesareexpressedasmean
ﬂuorescenceintensityunits(MFI)/10
5cells.*P0.005vs.control;†P0.05versusCPam.C,control;T2DM,type2diabetes.B:MonocyteTLR2
mRNAexpressionratiosincontrol(n23)andtype2diabetes(n23)subjectsbyreal-timeRT-PCRasdescribedin RESEARCH DESIGN AND METHODS.
18s mRNA is used as the housekeeping gene. Values are expressed as mean ratio  SD. *P  0.001 vs. control. C: Representative Western blot
depicting the TLR2 protein expression in pooled resting monocytes from three control subjects and three type 2 diabetic subjects. -Actin was used
asaloadingcontrolasdescribedin RESEARCH DESIGN AND METHODS.Eachassayisrepeatedfourtimes.D:TLR4surfaceproteinexpressionwasmeasured
in monocytes after LPS challenge in control (n  23) and type 2 diabetic (n  23) subjects by ﬂow cytometry as described in RESEARCH DESIGN AND
METHODS. Values are expressed as mean ﬂuorescence intensity units (MFI)/10
5 cells. *P  0.005 vs. control; †P  0.05 vs. C  LPS. E: Monocyte
TLR4 mRNA expression ratios in control (n  23) and type 2 diabetic (n  23) subjects by real-time RT-PCR as described in RESEARCH DESIGN AND
METHODS. 18s mRNA is used as the housekeeping gene. Values are expressed as mean ratio  SD. *P  0.005 vs. control. F: Representative Western
blot depicting the TLR4 protein expression in pooled resting monocytes from three control and three type 2 diabetic subjects. -Actin was used as a
loading control as described in RESEARCH DESIGN AND METHODS. Each assay is repeated four times. G: Release of cytokines in resting and activated
monocyte cell culture supernatants from control and type 2 diabetic subjects using Multiplex assay as described in RESEARCH DESIGN AND METHODS.
Values are expressed as pg/mg cell protein. *P  0.001 vs. untreated C; **P  0.005 vs. control (healthy control). C, untreated; LPS, lipopolysac-
charide, TLR4 ligand; Pam, Pam3CSK4, synthetic TLR2 ligand.
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MCP-1, and NF-B( r  0.42, r  0.35;
P  0.05) and between TLR4 and IL-1,
TNF- (r  0. 56, r  0.55, P  0.001),
IFN-,andNF-B(r0.46,r0.4,P
0.05). Because BMI was signiﬁcantly dif-
ferent between control and type 2 diabe-
tes, additional statistical analyses using
BMIasacovariantwereperformed.TLR2,
TLR4 (with and without Pam3CSK4 or
LPS), NF-B, endogenous ligands, CML,
andcytokinesweresigniﬁcantlyhigherin
type 2 diabetes compared with control
subjects(P0.001),whereasIL-1(P
0.09), IFN- (P  0.16), and endotoxin
(P  0.11) were no longer signiﬁcant.
CONCLUSIONS — The interactions
among inﬂammation, hyperglycemia, in-
sulin resistance, and type 2 diabetes have
clear implications for atherosclerosis via
the innate immune system. Besides being
activators of inﬂammation under hyper-
glycemia and insulin resistance (3,5–7),
both TLR2 and TLR4 are critical in
atherosclerosis (7). In this study, we
provided key evidence for increased
monocyteTLR2andTLR4expression,ac-
tivation,cofactorexpression,ligands,and
downstream signaling contributing to
systemic inﬂammation seen in type 2 di-
abetic subjects. Our observations signiﬁ-
cantlyaddtotheemergingroleofTLRsin
atherosclerosis and diabetes and are con-
sistent with other studies in this context
(3,7,11). Increased TLR2 and TLR4 ex-
pression is demonstrated in atheroscle-
rotic plaque macrophages and in animal
modelsofatherosclerosis.TLR2/4knock-
out mice on C57BL6, ApoE
	/	, and
LDLR
	/	 background and MyD88
knockout mice show reduced lesion size,
lipid content, and macrophage inﬁltra-
tioninplaquesandreducedinﬂammation
(22,23).
In two recent studies, we showed in-
creased TLR2 and TLR4 expression, TLR
ligands, intracellular signaling, and TLR-
mediated inﬂammation in monocytes
with signiﬁcant correlation to A1C levels
in type 1 diabetic patients (11,21). More-
over, TLR2/4 expression and activation is
increasedinhumanmonocytesunderhy-
perglycemia conditions (3). Reyna et al.
(15) have shown abnormal TLR4 expres-
sion in skeletal muscle of a small number
of insulin-resistant subjects, with little in-
formation on the TLR4-MyD88 signaling,
levels of TLR4 cofactors (CD14/MD-2),
TLR4 ligand (endotoxin), and its correla-
tiontoTLR4expression.Moreover,thein
vitroexperimentsinthisarticlewithmyo-
tubes and FFAs lacked appropriate endo-
toxin controls, and it is not clear if the
study subjects were on any cholesterol-
lowering medications, adding complexity
to the conclusions. Creely et al. (16)
showed increased TLR2 expression in the
adipose tissue of type 2 diabetes with
strongcorrelatestoendotoxinlevels,with
nochangeinTLR4expression.Thisstudy
is inconclusive in terms of the lack of
TLR4 expression, even under high endo-
toxinlevels,smallersamplesize,andmin-
imal patient medication details. Du et al.
(24) in a descriptive study showed that
monocytes from LADA, (latent autoim-
mune diabetes in adults) type 2 diabetic
patientsonsulfonylureatherapyhavesig-
niﬁcantly higher TLR4 and CD14 expres-
sion than healthy control subjects, with
no mechanistic details. In this context,
our study ﬁlls in all the above gaps se-
quentially: First, we provide data on both
TLR2andTLR4mRNA/proteinlevelsand
critical downstream signaling events that
follow their ligation in type 2 diabetes;
second, we determined cofactors re-
quired for TLR2/4 activation; third, we
demonstrated ligands in use for TLR2/4
activation; fourth, notably, we and others
have shown that statins, thiazolidinedio-
nes, and angiotensin receptor blockers
downregulate TLRs and our type 2 dia-
betic patients are not on any of these
drugs; ﬁfth, our TLR data showed signif-
icant correlation with major clinical esti-
mates of type 2 diabetes, namely adjusted
BMI, glucose, HOMA-IR, FFAs, ligands,
cytokines; and ﬁnally, data are shown for
both MyD88-dependent and -indepen-
dent signaling pathways, which may be
acting collectively.
In addition to the well-characterized
microbial ligands, several molecules of
the host origin (endogenous) have been
proposed to act as ligands for TLR2 and
TLR4,includingHMGB1,HSPs,andhya-
luronan (25), and were not examined in
type2diabetes.HMGB1isconsideredasa
“late” proinﬂammatory mediator in sep-
sis. It induces activation of intracellular
signaling pathways via TLR2, TLR4, and
the receptor for advanced glycation end
products (RAGEs), thus acting as an ex-
tracellular alarmin. HSPs also act as en-
dogenous ligands of TLR2 and TLR4.
HSP60andHSP70inducetheproduction
of proinﬂammatory cytokines via activa-
tionofTLR2andTLR4.Theinﬂammatory
effects of recombinant human HSP60




responses in murine alveolar macro-
phages in rheumatoid arthritis models
and other chronic inﬂammatory condi-
tions. Endotoxin is the most important
ligand required for TLR4 activation (14),
anditslevelsaresigniﬁcantlyincreasedin
type 2 diabetic patients. In the present
study, we show that type 2 diabetic pa-
tients have high circulating levels of
HMGB1, HSP60, HSP70, and hyaluro-
nan, which could trigger TLR2 and TLR4
activation, leading to a proinﬂammatory
state by the activation of TLR2/4, syner-
gistically with glucose, FFAs, and endo-
toxin. Our coimmunoprecipitation
studies further suggest an association be-
tween TLR2, TLR4, HMGB1, and HSP60.
Figure 1—Continued.
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care.diabetesjournals.org DIABETES CARE, VOLUME 33, NUMBER 4, APRIL 2010 865Figure 2—A: Endotoxin concentration in control (n  23) and type 2 diabetic (n  23) subjects was measured using Limulus Ameobocyte lysate
assay as described in RESEARCH DESIGN AND METHODS. Values are expressed as EU/ml. *P  0.05 vs. control. C, control; T2DM, type 2 diabetes. B:
HMGB1 concentration in control (n  23) and type 2 diabetic (n  23) subjects was measured using ELISA as described in RESEARCH DESIGN AND
METHODS. Values are expressed as ng/ml. *P  0.0001 vs. control. C: Hyaluronan concentration in control (n  23) and type 2 diabetic (n  23)
subjectswasmeasuredusingELISAasdescribedin RESEARCH DESIGN AND METHODS.Valuesareexpressedasng/ml.*P0.0001vs.control.D:HSP60
concentration in control (n  23) and type 2 diabetes (n  23) subjects was measured using ELISA as described in RESEARCH DESIGN AND METHODS.
Values are expressed as ng/ml. *P  0.0001 vs. control. E: HSP70 concentration in control (n  23) and type 2 diabetic (n  23) subjects was
measured using ELISA as described in RESEARCH DESIGN AND METHODS. Values are expressed as ng/ml. *P  0.0001 vs. control. F: Association of TLR2
withitsligandsandTLR6.RepresentativeWesternblotshowingenhancedexpressionofTLR6,HMGB1,hyaluronan,andHSP60inbasalcontroland
type 2 diabetes monocyte cell lysates immunoprecipitated with TLR2 antibody as detailed in RESEARCH DESIGN AND METHODS. -Actin was used as a
loading control. Each assay is repeated four times. IP, immunoprecipitation. G: Association of TLR4 with its ligands. Representative Western blot
showingenhancedexpressionofHMGB1,hyaluronan,andHSP60inbasalcontrolandtype2diabetesmonocytecelllysatesimmunoprecipitatedwith
TLR4 antibody as detailed in RESEARCH DESIGN AND METHODS. -Actin was used as a loading control. Each assay is repeated four times. H: Monocyte
TLRsignalinginthebasalstate.TLRdownstreamsignalingproteinsMyD88,pIRAK-1,Trif,IRF-3,TECAM-2,andNF-Bp65wereperformedusing
speciﬁc antibodies to the respective (phospho) proteins, as described in RESEARCH DESIGN AND METHODS using -actin as a loading and internal control
for MyD88, Trif, IRF-3, TECAM-2, and NF-B p65 and IRAK for pIRAK-1. Each blot is repeated four times with pooled monocytes from three
subjects.Densitometricratioscorroboratethedata.*P0.05vs.control.I:TheDNAbindingactivityofnuclearNF-Bp65incontrol(n23)and
type 2 diabetes (n  23) monocytes was assessed by ELISA as detailed in RESEARCH DESIGN AND METHODS in the basal state. Values are normalized to
milligramnuclearproteinandexpressedasmeanSD.*P0.05vs.control.J:Serumconcentrationofcytokines/chemokinesinstudysubjectswere
measured using Multiplex assays as described in RESEARCH DESIGN AND METHODS. Values are expressed as picograms per milliliter. *P  0.0001 vs.
control.K:Serumconcentrationofcytokines/chemokinesinstudysubjectsweremeasuredusingMultiplexassaysasdescribedin RESEARCH DESIGN AND
METHODS. Values are expressed as picograms per milliliter. *P  0.0001 vs. control.
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functional activation of TLRs and results
in cytokine production (3). TLR2 activity
requiresheterodimerizationwithTLR1or
TLR6 to recognize ligands. Using lucif-
erase reporter assays and real-time RT-
PCR, we showed that high glucose
induces TLR2 and TLR6 heterodimeriza-
tion, resulting in NF-B activation and
cytokine production (3). MD-2 is re-
quired for TLR4 ligation with endotoxin
(14). Here, we demonstrate that both
TLR6 and MD-2 mRNA expression is in-
creased in type 2 diabetic patients, sug-
gestingtheirrequirementforTLRligation
in type 2 diabetic patients.
TLRs mainly signal through the
adapter protein MyD88 via activation of
NF-B, resulting in the increased tran-
scription of inﬂammation-related genes,
such as those encoding indicated cyto-
kines (3,9,11). In addition, a MyD88-
independent pathway involving Trif is
essential to TLR3 and TLR4 signaling and
induces IFN-. In two recent studies, we
showed that activation of the MyD88
pathway is increased in monocytes ex-
posed to high glucose and in type 1 dia-
betic patients (3,9,11). In the present
study, we examined MyD88-dependent
and -independent TLR activation, by de-
termining IRF-3 and IFN- levels as a bi-
ologicalindicatorofMyD88-independent
activation.
Taken together, the novel ﬁndings of
this comprehensive study suggest that
Figure 2—Continued.
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TLR4 protein, mRNA, endogenous ligands,
and cofactors in type 2 diabetic patients,
which,inconcertwithhyperglycemia,con-
tributes to the increase in TLR2 and TLR4
signaling that results in the proinﬂamma-
tory state of type 2 diabetes. In future stud-
ies, we will address the mechanism of
synergistic effects of hyperglycemia, FFAs,
andendogenousligandsonTLR2andTLR4
expression and signaling.
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